The global healthcare technology (HealthTech) and medical technology (MedTech) mergers and acquisitions ecosystem in August 2026 operates under a regime defined by institutional market participants as "HealthTech 2.0" or "Industrial Maturity". Moving past the venture subsidised capital deployment of the post-pandemic era and the severe valuation compression experienced during 2022–2023, current market mechanics demonstrate disciplined capital allocation, rigorous underwriting

The European healthcare technology (HealthTech) mergers and acquisitions (M&A) landscape has entered a period of structured recalibration. Following post-pandemic market adjustments, current M&A activity reflects a structural transition away from speculative growth toward high-conviction, disciplined transactions. Capital deployment is heavily concentrated in platforms demonstrating clear operational leverage, defensible reimbursement pathways, and deep technological moats.

The global healthcare landscape is currently traversing a fundamental inflection point, marking a transition from a legacy of reactive medical intervention to a future defined by proactive, wellbeing centred support. For the better part of a century, the value of Medical Technology (MedTech) has been predicated on its capacity to diagnose, treat, and manage established diseases within clinical environments such as hospital wards, operating theatres, and diagnostic laboratori

This report provides a definitive analysis for venture capital (VC) investment in the value-based care (VBC) healthtech sector. While VBC represents a profound and necessary paradigm shift with a multi-trillion-dollar market opportunity, it is not an environment for unsophisticated capital. The core finding is a qualified "yes": venture capital should strategically back VBC healthtech, but only by targeting specific business models and deploying patient capital with a deep

The European healthcare technology (HealthTech) mergers and acquisitions (M&A) market is navigating a period of cautious yet discernible rebound in 2025. This resurgence is primarily propelled by improving macroeconomic conditions, substantial private equity dry powder and a pervasive strategic imperative for digital transformation across the healthcare ecosystem.